Pensive trading in the Dax

After last week’s recovery the Germany 30 has been a little slow getting out of the blocks.

It is going to be hard for the DAX not to be distracted by comments from the US this week, with Janet Yellen speaking on both Tuesday and Thursday. Last week’s non-farm payroll figures were worse than expected for the second time in a row, and have subsequently seen some asking for a change to the Federal Open Market Committee’s tapering timeline. Judging by the comments that have come from several of the voting members of that committee, an immediate change looks unlikely but pressure could build.

German traders will no doubt be keeping a wary eye out for results from UK banks this week as a number of issues will affect financial markets in both the UK and Germany.

Barclays has jumped the gun and posted some of its figures a day early creating more questions than answers.

Later in the week we will also see the release of quarterly GDP figures for a number of European countries including Germany.

Germany 30 chart

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.